PE20020301A1 - Uso del fosfato de estramustina en el tratamiento de metastasis osea - Google Patents
Uso del fosfato de estramustina en el tratamiento de metastasis oseaInfo
- Publication number
- PE20020301A1 PE20020301A1 PE2001000722A PE2001000722A PE20020301A1 PE 20020301 A1 PE20020301 A1 PE 20020301A1 PE 2001000722 A PE2001000722 A PE 2001000722A PE 2001000722 A PE2001000722 A PE 2001000722A PE 20020301 A1 PE20020301 A1 PE 20020301A1
- Authority
- PE
- Peru
- Prior art keywords
- phosphate
- stramustin
- treatment
- metastasis
- osea
- Prior art date
Links
- 229910019142 PO4 Inorganic materials 0.000 title abstract 4
- 239000010452 phosphate Substances 0.000 title abstract 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 title abstract 3
- 206010027476 Metastases Diseases 0.000 title abstract 2
- 230000009401 metastasis Effects 0.000 title abstract 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 2
- 210000000988 bone and bone Anatomy 0.000 abstract 2
- 229920002554 vinyl polymer Polymers 0.000 abstract 2
- ORGHESHFQPYLAO-UHFFFAOYSA-N vinyl radical Chemical class C=[CH] ORGHESHFQPYLAO-UHFFFAOYSA-N 0.000 abstract 2
- -1 CAMPTOTECHIN Chemical class 0.000 abstract 1
- 241000581364 Clinitrachus argentatus Species 0.000 abstract 1
- 229940045799 anthracyclines and related substance Drugs 0.000 abstract 1
- 230000000973 chemotherapeutic effect Effects 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 229930182470 glycoside Natural products 0.000 abstract 1
- 150000002338 glycosides Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000009103 reabsorption Effects 0.000 abstract 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
SE REFIERE AL USO DEL FOSFATO DE ESTRAMUSTINA ADMINISTRADO EN TERAPIA DE COMBINACION CON UN QUIMIOTERAPEUTICO ADICIONAL DENTRO DE UNA FORMULACION LIPOSOMAL SELECCIONADO DE DERIVADOS DE TAXANO, CAMPTOTECINA, GLICOSIDOS DE ANTRACICLINA, ETOPOSIDO, VINORELBINA, VINBLASTINA, CARBOPLATINO, CISPLATINO Y UN BISFOSFONATO ADICIONAL SELECCIONADO DE CLODRONATO, PALMIDRONATO, ETRIDONATO. EL FOSFATO DE ESTRAMUSTINA ES UN DERIVADO DE ESTRADIOL-17ß-FOSFATO UTIL PARA EL TRATAMIENTO DE LA REABSORCION OSEA Y ALIVIAR LOS SINTOMAS DE METASTASIS OSEA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/625,540 US6436913B1 (en) | 2000-07-25 | 2000-07-25 | Use of estramustine phosphate in the treatment of bone metastasis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20020301A1 true PE20020301A1 (es) | 2002-04-07 |
Family
ID=24506563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2001000722A PE20020301A1 (es) | 2000-07-25 | 2001-07-17 | Uso del fosfato de estramustina en el tratamiento de metastasis osea |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US6436913B1 (es) |
| EP (1) | EP1328264A4 (es) |
| JP (1) | JP2004504346A (es) |
| KR (1) | KR20030019612A (es) |
| CN (1) | CN1446086A (es) |
| AR (1) | AR029958A1 (es) |
| AU (1) | AU2001277115A1 (es) |
| BR (1) | BR0112721A (es) |
| CA (1) | CA2412392A1 (es) |
| MX (1) | MXPA03000313A (es) |
| PE (1) | PE20020301A1 (es) |
| WO (1) | WO2002007719A1 (es) |
| ZA (1) | ZA200210285B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0003201D0 (en) * | 2000-02-11 | 2000-04-05 | Pharmacia & Upjohn Spa | Method to potentiate the therapeutic efficacy of taxane and derivatives thereof |
| IT1318689B1 (it) * | 2000-09-12 | 2003-08-27 | Pharmacia & Upjohn Spa | Uso dell'arginina nella preparazione di un medicamento per lapreparazione e trattamento degli effetti collaterali associati alla |
| US20040014729A1 (en) * | 2001-07-23 | 2004-01-22 | Beryl Asp | Use of estramustine phosphate in the treatment of bone metastasis |
| CA2530279A1 (en) * | 2003-06-27 | 2005-01-06 | Akira Odani | Bisphosphonate complexes |
| JP2005055881A (ja) * | 2003-07-22 | 2005-03-03 | Fuji Photo Film Co Ltd | 描画方法および描画装置 |
| CN100340296C (zh) * | 2005-02-03 | 2007-10-03 | 山东蓝金生物工程有限公司 | 一种抗癌体内植入剂 |
| WO2011066379A2 (en) * | 2009-11-24 | 2011-06-03 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | METHOD OF REDUCING INTRATUMORAL pHe AND ACID-MEDIATED INVASION |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4634691A (en) * | 1980-10-07 | 1987-01-06 | The Procter & Gamble Company | Method for inhibiting tumor metastasis |
| US5597830A (en) | 1994-12-20 | 1997-01-28 | Warner-Lambert Company | Combination chemotherapy |
| BR9906425A (pt) * | 1998-03-27 | 2000-07-11 | Upjohn Co | Métodos para potencializar fosfato de estramustina intravenoso |
| WO2000074634A2 (en) * | 1999-06-03 | 2000-12-14 | Au Jessie L S | Methods and compositions for modulating cell proliferation and cell death |
-
2000
- 2000-07-25 US US09/625,540 patent/US6436913B1/en not_active Expired - Fee Related
-
2001
- 2001-07-17 PE PE2001000722A patent/PE20020301A1/es not_active Application Discontinuation
- 2001-07-23 AU AU2001277115A patent/AU2001277115A1/en not_active Abandoned
- 2001-07-23 AR ARP010103500A patent/AR029958A1/es not_active Application Discontinuation
- 2001-07-23 BR BR0112721-7A patent/BR0112721A/pt not_active IP Right Cessation
- 2001-07-23 CN CN01813244A patent/CN1446086A/zh active Pending
- 2001-07-23 JP JP2002513455A patent/JP2004504346A/ja not_active Withdrawn
- 2001-07-23 EP EP01954900A patent/EP1328264A4/en not_active Withdrawn
- 2001-07-23 KR KR10-2003-7001068A patent/KR20030019612A/ko not_active Withdrawn
- 2001-07-23 CA CA002412392A patent/CA2412392A1/en not_active Abandoned
- 2001-07-23 WO PCT/US2001/023179 patent/WO2002007719A1/en not_active Ceased
- 2001-07-23 MX MXPA03000313A patent/MXPA03000313A/es unknown
-
2002
- 2002-12-19 ZA ZA200210285A patent/ZA200210285B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2412392A1 (en) | 2002-01-31 |
| CN1446086A (zh) | 2003-10-01 |
| WO2002007719A1 (en) | 2002-01-31 |
| AU2001277115A1 (en) | 2002-02-05 |
| ZA200210285B (en) | 2003-12-19 |
| EP1328264A1 (en) | 2003-07-23 |
| US6436913B1 (en) | 2002-08-20 |
| JP2004504346A (ja) | 2004-02-12 |
| MXPA03000313A (es) | 2003-06-06 |
| KR20030019612A (ko) | 2003-03-06 |
| AR029958A1 (es) | 2003-07-23 |
| EP1328264A4 (en) | 2004-01-28 |
| BR0112721A (pt) | 2003-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRPK20041072B3 (hr) | Primjena docetaxela/doxorubicina/ciklofosfamida uadjuvantnoj terapiji karcinoma dojke i jajnika | |
| BR0115162A (pt) | Tratamentos antitumorais eficazes | |
| AR033555A1 (es) | Producto para el tratamiento del carcinoma de receptor de estrogeno positivo, y uso de dicho producto para preparar medicamentos | |
| PA8479201A1 (es) | Derivados del acido hidroxi-pipecolato hidroxamico | |
| AR023806A1 (es) | Uso de una mezcla de peptidos para la manufactura de un agente terapeutico para la profilaxis y/o el tratamiento del cancer, las composicionesfarmaceuticas y vacunas que contienen dicha mezcla y los procedimientos de preparacion de dichas composiciones y vacunas | |
| BR0107869A (pt) | Composições farmacêuticas eletrogiradas | |
| BR9906581A (pt) | Processo para administração de taxano encapsulado em lipossomos | |
| ES2161085T3 (es) | Formulaciones que contienen oxaliplatino. | |
| BR0109515A (pt) | Derivados da apomorfina e métodos para seu uso | |
| BR0117063A (pt) | Uso de ciclopamina no tratamento de carcinoma de células basais e outros tumores | |
| AR015744A1 (es) | Uso de dexmedetomidina para sedacion en terapia intensiva | |
| PE20020301A1 (es) | Uso del fosfato de estramustina en el tratamiento de metastasis osea | |
| ECSP034766A (es) | Una combinacion que comprende combretastatina y agentes anticancerigenos | |
| AR019699A1 (es) | Composicion farmaceutica para el tratamiento de disfuncion de la evacuacion y uso de la misma para la preparacion de un agente terapeutico | |
| PT1085884E (pt) | Combinacao de compostos seleniferos com gemcitabina ou mitomicina c | |
| MXPA03003125A (es) | Liposomas encapsulando farmacos anticancerosos y uso de los mismos en el tratamiento de tumores malignos. | |
| BRPI0518250A2 (pt) | tratamentos anticÂncer | |
| CY1108787T1 (el) | Συνθεση για ενισχυση χημειοθεραπευτικων παραγοντων καρκινου | |
| AR036321A1 (es) | Metodo y formulacion farmaceutica para el tratamiento de la discinesia de aparicion tardia. | |
| ECSP034530A (es) | Derivados de 6-metil-tramadol sustituido en o | |
| ID27253A (id) | Penggunaan turunan-turunan kampotesin dengan toksisitas gastrointestinal yang tereduksi | |
| EA200300427A1 (ru) | Противоопухолевая терапия, включающая производные дистамицина | |
| PE20020466A1 (es) | Combinacion de raloxifeno y exemestano para el tratamiento de cancer de mama | |
| TR200302134T4 (tr) | 2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı. | |
| ES2181915T3 (es) | Ctla-8 en combinacionpn con g-csf y il-6, y uso de ctla-8 para tratar infecciones. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |